ChemoCentryx to Hold First Quarter 2017 Financial Results Conference Call on Wednesday, May 10, 2017
April 27 2017 - 8:30AM
ChemoCentryx, Inc., (Nasdaq:CCXI), today announced that the
Company's first quarter 2017 financial results will be released
after market close on Wednesday, May 10, 2017. ChemoCentryx
executive management will host a conference call beginning at 5:00
p.m. Eastern Time on Wednesday, May 10, 2017, to discuss these
results and to answer questions.
To participate by telephone, please dial (877) 303-8028
(Domestic) or (760) 536-5167 (International). The conference ID
number is 13584608. A live and archived audio webcast can be
accessed through the Investors section of the Company's website at
www.ChemoCentryx.com. The archived webcast will remain available on
the Company's website for fourteen (14) days following the
call.
About ChemoCentryxChemoCentryx is a
biopharmaceutical company developing new medications targeted at
inflammatory and autoimmune diseases, and cancer. ChemoCentryx
targets the chemokine and chemoattractant systems to discover,
develop and commercialize orally-administered therapies.
ChemoCentryx is currently focusing on its late stage drug
candidates for patients with rare kidney diseases, avacopan
(CCX168) and CCX140.
Avacopan is an orally-administered small molecule that is a
selective inhibitor of the complement C5a receptor, or C5aR.
Avacopan is in Phase III development for the treatment of
anti-neutrophil cytoplasmic auto-antibody-associated vasculitis
(AAV). In clinical studies to date, avacopan was shown to be safe,
well tolerated and provided effective control of the disease while
allowing elimination of high-dose steroids, part of the current
standard of care. Avacopan is also being developed in patients with
C3 glomerulopathy (C3G) and atypical hemolytic uremic syndrome
(aHUS). The U.S. Food and Drug Administration has now granted
avacopan orphan-drug designation for three indications, AAV, C3G
and aHUS. The European Commission has granted orphan medicinal
product designation for avacopan for the treatment of two forms of
AAV: microscopic polyangiitis and granulomatosis with polyangiitis
(formerly known as Wegener's granulomatosis). Avacopan was
also granted access to the European Medicines Agency's (EMA)
PRIority MEdicines (PRIME) initiative, which supports accelerated
assessment of investigational therapies addressing unmet medical
need.
The Company's other late stage drug candidate is CCX140, an
inhibitor of the chemokine receptor known as CCR2, which is
currently being developed for patients with focal segmental
glomerulosclerosis (FSGS), a debilitating kidney disease.
ChemoCentryx's Kidney Health Alliance with Vifor Pharma provides
Vifor Pharma with exclusive rights to commercialize avacopan and
CCX140 in markets outside of the U.S. and China.
ChemoCentryx also has early stage drug candidates that target
chemoattractant receptors in other Inflammatory and autoimmune
diseases and in cancer.
Source: ChemoCentryx, Inc.
CCXI-G
Contacts:
Susan M. Kanaya
Executive Vice President,
Chief Financial and Administrative Officer
investor@chemocentryx.com
Media:
Denise Powell
denise@redhousecomms.com
510.703.9491
Investors:
Steve Klass, Burns McClellan
212.213.0006
sklass@burnsmc.com
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Mar 2024 to Apr 2024
ChemoCentryx (NASDAQ:CCXI)
Historical Stock Chart
From Apr 2023 to Apr 2024